Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Pseudoprogression after stereotactic body radiotherapy.

Frechette KM, Brown LC, Aubry MC, Wigle DA, Olivier KR.

J Thorac Oncol. 2014 Apr;9(4):e29-30. doi: 10.1097/JTO.0000000000000067. No abstract available.

2.

Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer.

Xia T, Li H, Sun Q, Wang Y, Fan N, Yu Y, Li P, Chang JY.

Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):117-25. Epub 2006 Jun 9.

PMID:
16765528
3.

[An analysis of 20 consecutive patients treated with stereotactic body radiotherapy on Novalis Tx(®) for stage I non-small-cell lung cancer].

Guillerme F, Clavier JB, Schumacher C, Falcoz PE, Bourrhala K, Santelmo N, Hassler S, Schott R, Quoix E, Massard G, Noël G.

Cancer Radiother. 2013 Jul-Aug;17(4):272-81. doi: 10.1016/j.canrad.2013.01.021. Epub 2013 May 24. French.

PMID:
23712043
4.

Stereotactic radiotherapy (SBRT) as a sole or salvage therapy in non-small cell lung cancer patients.

Dworzecki T, Idasiak A, Syguła D, Dworzecka U, Suwiński R.

Neoplasma. 2012;59(1):114-20.

PMID:
22103905
5.

Predictors of radiotherapy induced bone injury (RIBI) after stereotactic lung radiotherapy.

Taremi M, Hope A, Lindsay P, Dahele M, Fung S, Purdie TG, Jaffray D, Dawson L, Bezjak A.

Radiat Oncol. 2012 Sep 17;7:159. doi: 10.1186/1748-717X-7-159.

6.

A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer.

Murphy JD, Christman-Skieller C, Kim J, Dieterich S, Chang DT, Koong AC.

Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1420-6. doi: 10.1016/j.ijrobp.2009.09.075. Epub 2010 Apr 14.

PMID:
20399033
7.

Treatment of large stage I-II lung tumors using stereotactic body radiotherapy (SBRT): planning considerations and early toxicity.

Ong CL, Palma D, Verbakel WF, Slotman BJ, Senan S.

Radiother Oncol. 2010 Dec;97(3):431-6. doi: 10.1016/j.radonc.2010.10.003.

PMID:
20971523
8.

Vocal cord paralysis after stereotactic body radiation therapy to the left lung apex.

Carpenter TJ, Rosenzweig KE.

J Thorac Oncol. 2014 Nov;9(11):e80-1. doi: 10.1097/JTO.0000000000000208. No abstract available.

9.

Untoward clinical effects after stereotactic radiosurgery for intracranial arteriovenous malformations.

Sutcliffe JC, Forster DM, Walton L, Dias PS, Kemeny AA.

Br J Neurosurg. 1992;6(3):177-85.

PMID:
1632916
10.

Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver.

Andolino DL, Forquer JA, Henderson MA, Barriger RB, Shapiro RH, Brabham JG, Johnstone PA, Cardenes HR, Fakiris AJ.

Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):692-7. doi: 10.1016/j.ijrobp.2010.03.020. Epub 2011 Feb 1.

PMID:
21288656
11.

[Stereotactic body radiation therapy for early non-small cell lung cancer].

Zhang HQ, Li MH, Yu JM.

Zhonghua Zhong Liu Za Zhi. 2011 Aug;33(8):561-3. Review. Chinese. No abstract available.

PMID:
22325212
12.

Hypofractionated stereotactic radiotherapy for primary and secondary intrapulmonary tumors: first results of a phase I/II study.

Ernst-Stecken A, Lambrecht U, Mueller R, Sauer R, Grabenbauer G.

Strahlenther Onkol. 2006 Dec;182(12):696-702.

13.

Lung stereotactic body radiation therapy (SBRT) delivered over 4 or 11 days: a comparison of acute toxicity and quality of life.

Jain S, Poon I, Soliman H, Keller B, Kim A, Lochray F, Yeung L, Cheung P.

Radiother Oncol. 2013 Aug;108(2):320-5. doi: 10.1016/j.radonc.2013.06.045. Epub 2013 Aug 27.

PMID:
23993401
14.

Postradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression?

Walker AJ, Ruzevick J, Malayeri AA, Rigamonti D, Lim M, Redmond KJ, Kleinberg L.

Future Oncol. 2014 May;10(7):1277-97. doi: 10.2217/fon.13.271. Review.

15.

Stereotactic body radiotherapy: do central lung tumors still represent a 'no-fly zone'?.

Senan S.

Onkologie. 2012;35(7-8):406-7. doi: 10.1159/000341091. Epub 2012 Jun 27. No abstract available.

16.

Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer.

Matsuo Y, Shibuya K, Nagata Y, Takayama K, Norihisa Y, Mizowaki T, Narabayashi M, Sakanaka K, Hiraoka M.

Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1104-11. doi: 10.1016/j.ijrobp.2009.12.022. Epub 2010 May 14.

PMID:
20472343
17.

Preliminary report of late recurrences, at 5 years or more, after stereotactic body radiation therapy for non-small cell lung cancer.

Matsuo Y, Shibuya K, Nagata Y, Norihisa Y, Narabayashi M, Sakanaka K, Ueki N, Mizowaki T, Hiraoka M.

J Thorac Oncol. 2012 Feb;7(2):453-6. doi: 10.1097/JTO.0b013e31823c5b29.

18.

[Brain radiation necrosis after stereotactic radiotherapy of the resection cavity for intracranial metastases: analysis of the literature from four cases].

Doré M, Lefebvre L, Delpon G, Thillays F.

Cancer Radiother. 2015 Apr;19(2):111-9. doi: 10.1016/j.canrad.2014.10.008. Epub 2015 Jan 5. Review. French.

PMID:
25573799
19.

Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy.

Yamamoto T, Kadoya N, Shirata Y, Koto M, Sato K, Matsushita H, Sugawara T, Umezawa R, Kubozono M, Ishikawa Y, Kozumi M, Takahashi N, Ito K, Katagiri Y, Takeda K, Jingu K.

Radiat Oncol. 2015 Feb 7;10:35. doi: 10.1186/s13014-015-0343-6.

20.

Stereotactic body radiotherapy for second pulmonary nodules after operation for an initial lung cancer.

Nishiyama K, Kodama K, Teshima T, Tada H.

Jpn J Clin Oncol. 2015 Oct;45(10):947-52. doi: 10.1093/jjco/hyv113. Epub 2015 Aug 3.

PMID:
26238818

Supplemental Content

Support Center